Jubilant Life Sciences is trading higher by over 6% at Rs 135 on BSE after the pharmaceutical company said it has received approval from the US health regulator to market generic version AstraZeneca's Seroquel used for the treatment of schizophrenia and acute manic episodes associated with bipolar disorder. The company expects to launch this product in Q4 FY14.
The abbreviated new drug applications (ANDAs) approval from the US Food and Drug Administration is for Quetiapine Fumarate tablet, generic version AstraZeneca's Seroquel is in strength of 25 mg (base), Jubilant Life Sciences said in a statement.
The company said the current total market size for this product $59 million per annum according to IMS.
A combined around 200,000 shares have changed hands on the counter in early morning deals on the BSE and NSE.
The abbreviated new drug applications (ANDAs) approval from the US Food and Drug Administration is for Quetiapine Fumarate tablet, generic version AstraZeneca's Seroquel is in strength of 25 mg (base), Jubilant Life Sciences said in a statement.
The company said the current total market size for this product $59 million per annum according to IMS.
A combined around 200,000 shares have changed hands on the counter in early morning deals on the BSE and NSE.
